Selective 5‐hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia?
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background: Abnormalities of gut motility and visceral pain perception are both thought to be involved in the pathogenesis of irritable bowel syndrome and may be susceptible to modulation by drugs affecting the various 5‐HT receptor subtypes. The aim of this study was to investigate the therapeutic potential of a 5‐HT 3 antagonist in irritable bowel syndrome. Methods: Fifty patients with irritable bowel syndrome were treated with ondansetron, a highly selective 5‐HT 3 antagonist, in a double‐blind, placebo‐controlled cross‐over study. In addition to assessing its effect on the classical symptoms of irritable bowel syndrome (abdominal pain, distension and disordered bowel habit) its effect on symptoms often seen in irritable bowel syndrome, but more commonly associated with functional dyspepsia, was also examined. Results: Ondansetron reduced bowel frequency (P=0.035) and improved stool consistency (P=0.002) in diarrhoea predominant irritable bowel syndrome and did not cause a deterioration of bowel habit in constipation predominant subjects. No statistically significant improvement was seen for abdominal pain or distension, although those patients who did respond were approximately twice as likely to be taking ondansetron than placebo. It was also found that ondansetron significantly improved the upper gastrointestinal symptoms of post‐prandial epigastric discomfort (P=0.008), flatulence (P=0.022) and heartburn (P=0.003). Conclusion: The results of this study justify evaluation of the therapeutic potential of selective 5‐HT antagonists in both functional dyspepsia and irritable bowel syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Non-colonic features of irritable bowel syndrome.
Whorwell, P. J., McCallum, M., Creed, F. H., & Roberts, C. T. (1986) · Gut · doi:10.1136/gut.27.1.37 · Cited by 473
Self-citation
Cited by
Functional Gastroduodenal Disorders
Tack, J., Talley, N. J., Camilleri, M., Holtmann, G., Hu, P., Malagelada, J.-R., & Stanghellini, V. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.059 · Cited by 2,418
Gershon, M. D., & Tack, J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.11.002 · Cited by 1,563
Spiller, R. C., Jenkins, D., Thornley, J. P., Hebden, J. M., Wright, T., Skinner, M., & Neal, K. R. (2000) · Gut · doi:10.1136/gut.47.6.804 · Cited by 1,155
“27 Most studies of diarrhoea predominant IBS treated with 5-HT 3 antagonists have reported an improvement in diarrhoea 28 29 and a reduction in visceral hypersensitivity.”
BackgroundACG Clinical Guideline: Management of Irritable Bowel Syndrome
Lacy, B. E., Pimentel, M., Brenner, D. M., Chey, W. D., Keefer, L. A., Long, M. D., & Moshiree, B. (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001036 · Cited by 893
Camilleri, M., Northcutt, A. R., Kong, S., Dukes, G. E., McSorley, D., & Mangel, A. W. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02033-x · Cited by 556
Metadata
- Authors
- MAXTON, D. G., MORRIS, J., & WHORWELL, P. J.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 1996-08
- Volume
- 10
- Issue
- 4
- Pages
- 595-599
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2011663436
- Cited by
- 96
- References
- 1
- FWCI
- 5.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective 5‐hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia? https://app.cochat.ai/papers/10.1046/j.1365-2036.1996.30172000.x
- The paper
- MAXTON, D. G., MORRIS, J., & WHORWELL, P. J. (1996). Selective 5‐hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia? Alimentary Pharmacology & Therapeutics. https://doi.org/10.1046/j.1365-2036.1996.30172000.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.